AI ASSISTANT
Ask DrugCentral
Explore drug information in your own words.
Type a question in the search bar above to get started. Each question is answered independently.
Try a sample question
Select a question to fill the search bar, then submit it or edit it first.
AI can make mistakes. Verify answers against the original sources before relying on them.
benoxaprofen 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |
| Stem definition | Drug id | CAS RN |
|---|---|---|
| anti-inflammatory agents, ibuprofen derivatives | 311 | 51234-28-7 |
Description:
| Molecule | Description |
|---|---|
|
Synonyms:
|
|
Drug dosage:
None
ADMET properties:
| Property | Value | Reference |
|---|---|---|
| BDDCS (Biopharmaceutical Drug Disposition Classification System) | 2 | Hosey CM, Chan R, Benet LZ |
| S (Water solubility) | 0.05 mg/mL | Bocci G, Oprea TI, Benet LZ |
| BA (Bioavailability) | 95 % |
Predicted pharmacokinetic/toxicological properties (PK-AZ):
| Property | Description | Value | Unit | Confidence | Similarity |
|---|---|---|---|---|---|
| azlogd74 | LogD at pH 7.4 | 1.242 | High | 1 | |
| caco2-efflux | Caco-2 efflux ratio (BA/AB) | 0.944 | High | 1 | |
| caco2-intrinsic-papp | Caco-2 intrinsic apparent permeability | 177.828 | 10^-6 cm/s | High | 1 |
| dh-clint | Dog hepatocyte intrinsic clearance | 3.451 | uL/min/10^6 cells | High | 1 |
| dppb | Dog plasma protein binding (% unbound) | 0.510 | % | High | 1 |
| fcs-ppb | Fetal calf serum protein binding (% unbound) | 1.470 | % | High | 1 |
| herg | hERG pIC50 | 4.480 | pIC50 | High | 1 |
| hh-clint | Human hepatocyte intrinsic clearance | 2.685 | uL/min/10^6 cells | High | 1 |
| hlm-clint | Human liver microsomal intrinsic clearance | 3.048 | uL/min/mg protein | High | 1 |
| hppb | Human plasma protein binding (% unbound) | 0.400 | % | High | 1 |
| kinase-safety-class | ACVR2B,AURKA,AXL,BRAF,CDK9,EIF2AK3,ERBB2,GRK2,IKBKB,MAPK7,PDK1,PDK2,PDK4,PIK3CB,PIK3CG,PRKDC,TGFBR1 | 17 | |||
| kinase-selectivity-class | ACVR2B,EIF2AK3,GRK2 | 3 | |||
| mdck-mdr1-efflux | MDCK-MDR1 efflux ratio | 6.501 | High | 1 | |
| mh-clint | Mouse hepatocyte intrinsic clearance | 9.141 | High | 1 | |
| mppb | Mouse plasma protein binding (% unbound) | 2.590 | High | 1 | |
| nih-mdck-mdr1-efflux | NIH MDCK-MDR1 efflux ratio | 0.733 | High | 1 | |
| pfas-class | PFAS structural alert (1 = True, 0 = False) | 0 | |||
| pppb | Pig plasma protein binding (% unbound) | 1.130 | % | High | 1 |
| rh-clint | Rat hepatocyte intrinsic clearance | 1.186 | uL/min/10^6 cells | High | 1 |
| rh-fuinc | Rat hepatocyte fraction unbound in incubation | 55.670 | % | High | 1 |
| rppb | Rat plasma protein binding (% unbound) | 0.440 | % | High | 1 |
| solubility-dd | Solubility at pH 7.4 in DMSO | 941.890 | uM | High | 1 |
Approvals:
| Date | Agency | Company | Orphan |
|---|---|---|---|
| April 19, 1982 | FDA |
FDA Adverse Event Reporting System (Female)
None
FDA Adverse Event Reporting System (Male)
None
FDA Adverse Event Reporting System (Geriatric)
None
FDA Adverse Event Reporting System (Pediatric)
None
Pharmacologic Action:
| Source | Code | Description |
|---|---|---|
| ATC | M01AE06 | MUSCULO-SKELETAL SYSTEM ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS, NON-STEROIDS Propionic acid derivatives |
| MeSH PA | D000700 | Analgesics |
| MeSH PA | D000893 | Anti-Inflammatory Agents |
| MeSH PA | D000894 | Anti-Inflammatory Agents, Non-Steroidal |
| MeSH PA | D003879 | Dermatologic Agents |
| MeSH PA | D004791 | Enzyme Inhibitors |
| MeSH PA | D016859 | Lipoxygenase Inhibitors |
| MeSH PA | D018373 | Peripheral Nervous System Agents |
| MeSH PA | D018501 | Antirheumatic Agents |
| MeSH PA | D018689 | Sensory System Agents |
| MeSH PA | D018712 | Analgesics, Non-Narcotic |
| CHEBI has role | CHEBI:35475 | non-steroidal anti-inflammatory drug |
| CHEBI has role | CHEBI:35481 | non-narcotic analgesic |
| CHEBI has role | CHEBI:35493 | antipyretic |
| CHEBI has role | CHEBI:50748 | antipsoriatic |
| CHEBI has role | CHEBI:50908 | hepatotoxic agent |
| CHEBI has role | CHEBI:50909 | nephrotoxic agent |
| CHEBI has role | CHEBI:64018 | protein kinase C agonist |
| CHEBI has role | CHEBI:64964 | EC 1.13.11.34 (arachidonate 5-lipoxygenase) inhibitor |
Related Drugs by ATC class:
M01AE Propionic acid derivatives 21 drugs
Drug Use | Suggest Off label Use Form| |View source of the data|
| Disease | Relation | SNOMED_ID | DOID |
|---|---|---|---|
| Rheumatoid arthritis | indication | 69896004 | DOID:7148 |
🐶 Veterinary Drug Use
None
🐶 Veterinary products
None
Acid dissociation constants calculated using MoKa v3.0.0
| Dissociation level | Dissociation constant | Type (acidic/basic) |
|---|---|---|
| pKa1 | 3.05 | acidic |
Orange Book patent data (new drug applications)
None
Orange Book exclusivity data (new drug applications)
None
Bioactivity Summary:
| Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
|---|---|---|---|---|---|---|---|---|---|
| Arachidonate 5-lipoxygenase | Enzyme | INHIBITOR | KEGG DRUG | KEGG DRUG | |||||
| Bile salt export pump | Transporter | IC50 | 4 | CHEMBL |
External reference:
| ID | Source |
|---|---|
| D03080 | KEGG_DRUG |
| 70062-36-1 | SECONDARY_CAS_RN |
| 51234-86-7 | SECONDARY_CAS_RN |
| C0053111 | UMLSCUI |
| CHEBI:76114 | CHEBI |
| CHEMBL340978 | ChEMBL_ID |
| DB04812 | DRUGBANK_ID |
| C011677 | MESH_SUPPLEMENTAL_RECORD_UI |
| 39941 | PUBCHEM_CID |
| 3896 | INN_ID |
| 17SZX404IM | UNII |
| 002390 | NDDF |
| 396197001 | SNOMEDCT_US |
| 17SZX404IM | INXIGHT DRUGS |
Pharmaceutical products:
None